目的 对比利妥昔单抗（rituximab，RTX）低剂量（200 mg/m2）与推荐剂量（375 mg/m2）重复使用治疗频复发型肾病综合征（frequently relapsing nephrotic syndrome，FRNS）或激素依赖型肾病综合征（steroid-dependent nephrotic syndrome，SDNS）维持缓解的疗效和安全性。 方法 采用随机对照试验研究法，选择2020年9月—2021年12月在安徽省儿童医院儿童肾脏科接受系统治疗的29例FRNS/SDNS患儿为研究对象，按随机数字表法分为推荐剂量组（n=14）和低剂量组（n=15）。分析比较两组患儿的一般特征、RTX治疗前后CD19变化、复发次数、糖皮质激素使用剂量、RTX不良反应及住院费用等差异。 结果 与治疗前相比，低剂量组与推荐剂量组在应用RTX后均能使B淋巴细胞耗竭，且复发次数减少、糖皮质激素使用剂量下降（P<0.05）。低剂量组RTX治疗后的临床疗效与推荐剂量组相当（P>0.05）；而低剂量组第2~4次住院费用下降（P<0.05）。两组在使用RTX过程中及后期随访中无严重不良反应，发生的不良反应差异无统计学意义（P>0.05）。 结论 低剂量与推荐剂量重复RTX治疗临床疗效和安全性相当，可显著降低FRNS/SDNS复发次数及糖皮质激素使用剂量，在整个治疗周期内无明显不良反应，适合临床推广。
Abstract
Objective To study the efficacy and safety of repeated application of rituximab (RTX) at a low dose (200 mg/m2) versus the recommended dose (375 mg/m2) for remission maintenance in frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Methods A randomized controlled trial was conducted for 29 children with FRNS/SDNS who received systemic treatment in the Department of Nephrology, Anhui Provincial Children's Hospital, from September 2020 to December 2021. These children were divided into a recommended dose group (n=14) and a low dose group (n=15) using a random number table. The two groups were compared in terms of general characteristics, changes in CD19 expression after RTX treatment, number of relapses, glucocorticoid dose, adverse reactions of RTX, and hospital costs. Results After RTX treatment, both the low dose group and the recommended dose group achieved B-lymphocyte depletion and had significant reductions in the number of relapses and glucocorticoid dose (P<0.05). The low dose group had a comparable clinical effect to the recommended dose group after RTX treatment (P>0.05), and the low dose group had a significant reduction in hospital costs for the second, third, and fourth times of hospitalization (P<0.05). There were no serious adverse reactions in either group during RTX treatment and late follow-up, and there was no significant difference in adverse reactions between the two groups (P>0.05). Conclusions Repeated RTX treatment at a low dose has comparable clinical efficacy and safety to that at the recommended dose and can significantly reduce the number of FRNS/SDNS relapses and the amount of glucocorticoids used, with little adverse effect throughout the treatment cycle. Therefore, it holds promise for clinical application.
关键词
肾病综合征 /
利妥昔单抗 /
频复发 /
激素依赖 /
儿童
Key words
Nephrotic syndrome /
Rituximab /
Frequent relapse /
Steroid dependence /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Basu B, Sander A, Roy B, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial[J]. JAMA Pediatr, 2018, 172(8): 757-764. PMID: 29913001. PMCID: PMC6142920. DOI: 10.1001/jamapediatrics.2018.1323.
2 Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children[J]. Cochrane Database Syst Rev, 2020, 4(4): CD002290. PMID: 32297308. PMCID: PMC7160055. DOI: 10.1002/14651858.CD002290.pub5.
3 Iijima K, Sako M, Oba M, et al. Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome[J]. J Am Soc Nephrol, 2022, 33(2): 401-419. PMID: 34880074. PMCID: PMC8819987. DOI: 10.1681/ASN.2021050643.
4 Basu B, Preussler S, Sander A, et al. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome[J]. BMC Nephrol, 2020, 21(1): 520. PMID: 33256621. PMCID: PMC7706288. DOI: 10.1186/s12882-020-02153-5.
5 Nagano C, Sako M, Kamei K, et al. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)[J]. BMC Nephrol, 2019, 20(1): 293. PMID: 31375087. PMCID: PMC6679488. DOI: 10.1186/s12882-019-1470-3
6 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J]. 中华儿科杂志, 2017, 55(10): 729-734. PMID: 29050108. DOI: 10.3760/cma.j.issn.0578-1310.2017.10.003.
7 张涛, 沈茜, 徐虹, 等. 利妥昔单抗治疗儿童原发性难治性肾病综合征疗效及其影响因素的自身前后对照研究[J].中国循证儿科杂志, 2018, 13(3): 161-165. DOI:10.3969/j.issn.1673-5501.2018.03.001.
8 王道静, 王筱雯, 丁娟娟, 等. 利妥昔单抗在儿童难治性肾病综合征中的疗效评估[J]. 中华实用儿科临床杂志, 2022, 37(19): 1473-1477. DOI:10.3760/cma.j.cn101070-20220216-00162.
9 Chan EY, Webb H, Yu E, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes[J]. Kidney Int, 2020, 97(2): 393-401. PMID: 31874801. DOI: 10.1016/j.kint.2019.09.033.
10 Kamei K, Ishikura K, Sako M, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab[J]. Pediatr Nephrol, 2017, 32(11): 2071-2078. PMID: 28664242. DOI: 10.1007/s00467-017-3718-0.
11 Hogan J, Dossier C, Kwon T, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome[J]. Pediatr Nephrol, 2019, 34(2): 253-259. PMID: 30109447. DOI: 10.1007/s00467-018-4052-x.
12 Sellier-Leclerc AL, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery[J]. Nephrol Dial Transplant, 2012, 27(3):1083-1089. PMID: 21810762. DOI: 10.1093/ndt/gfr405.
13 Chan EY, Yu ELM, Angeletti A, et al. Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study[J]. J Am Soc Nephrol, 2022, 33(6): 1193-1207. PMID: 35354600. PMCID: PMC9161790. DOI: 10.1681/ASN.2021111472.
14 林力, 任红, 谢静远, 等. 利妥昔单抗对肾小球疾病患者血淋巴细胞及免疫球蛋白的影响[J]. 中华肾脏病杂志, 2021, 37(2): 81-86. DOI:10.3760/cma.j.cn441217-20200316-00015.
15 Chen Y, Shen Q, Dong M, et al. Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome[J]. 2021, 12: 725665. PMID: 34539407. PMCID: PMC8443776. DOI: 10.3389/fphar.2021.725665.
16 Luciani L, Ninove L, Zandotti C, et al. Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease[J]. Mult Scler, 2021, 27(2): 320-323. PMID: 32584194. DOI: 10.1177/1352458520923978.
基金
安徽医科大学校科研基金项目（2021xkj231）。
PDF(557 KB)
